Genascence
Chemicals & Related Products · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
3225 Ash Palo Alto St, Palo Alto, Califo...Phone Number
(707) 530-2523Website
www.genascence.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Genascence
Genascence, a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, is developing life-changing treatments for highly prevalent conditions affecting millions of people. Genascence was founded in 2017 and is based in California, the United States.Explore more
Genascence Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Genascence your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Genascence launches new products
Funding: Get notified immidiatlly once Genascence has new funding data
Check out if Genascence is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Genascence recently announced quarterly report
Check if Genascence has recently received funding, and reach out quickly before it becomes old news!
Genascence, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Genascence had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Genascence
Recommended Actions
Find VP level buyers at Genascence
Find more new buyers
Compare Similar Companies to Genascence
Compare insights from companies similar to Genascence, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Genascence is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Genascence is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Genascence.
Genascence financials insights
Gather financial insights about Genascence, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$10.5M
Genascence Tech Stack
A closer look at the technologies used by Genascence
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Event
Person-Based
Events, Search, Medical Research
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Funding
Genascence News & Media
Genascence Phase 1b DONATELLO Trial Evaluating Potential First-in-Class Gene Therapy for Knee Osteoarthritis (OA) Meets Primary Endpoint Showing GNSC-001 Was Safe and Well Tolerated Across Multiple Dosing Arms
PALO ALTO, Calif.--(BUSINESS WIRE)--Genascence Corporation (“Genascence”), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today announced positive 12-month safety and biomarker results from the Phase 1b DONATELLO clinical trial evaluating GNSC-001, a potential first-in-class gene therapy blocking interleukin 1 (IL-1) for the treatment of knee osteoarthritis (OA). Results from the 12-month analysis showed the study meGenascence Granted FDA Fast Track Designation for GNSC-001 in Patients with Osteoarthritis (OA) of the Knee
GNSC-001 is first gene therapy for prevalent musculoskeletal diseases like OA GNSC-001 is designed to offer long-term, sustained inhibition of IL-1 following a single injection into the affected joint; IL-1 is a key mediator involved in pathogenesis of OA OA affects more than 30 million...Genascence Appoints Jeymi Tambiah as Chief Medical Officer
—Accomplished physician-scientist with more than 15 years' biopharmaceutical industry experience in medical affairs, clinical development, and drug development —Visionary leader skilled at leveraging scientific and clinical expertise to build innovative first-in-class therapeutic programs...Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001 Gene Therapy for Knee Osteoarthritis (OA)
Phase 1b clinical trial in the U.S. is actively recruiting patients with OA at 10 sites Initial six-month data expected fourth quarter of 2024 PALO ALTO, Calif., Jan. 3, 2024 Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of...
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Genascence
Sign Up For FreeTo access detailed company insights
Genascence, a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, is developing life-changing treatments for highly prevalent conditions affecting millions of people. Genascence was founded in 2017 and is based in California, the United States.... Read More
